Intravascular hemolysis activates complement ...
Type de document :
Article dans une revue scientifique
PMID :
URL permanente :
Titre :
Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles.
Auteur(s) :
Merle Nicolas, S [Auteur]
Unité de Catalyse et Chimie du Solide - UMR 8181 [UCCS]
Grunenwald, Anne [Auteur]
Rajaratnam, Helena [Auteur]
Gnemmi, Viviane [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Frimat, Marie [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lille Inflammation Research International Center (LIRIC) - U995
Figueres, Marie-Lucile [Auteur]
Knockaert, Samantha [Auteur]
Bouzekri, Sanah [Auteur]
Charue, Dominique [Auteur]
Noe, Remi [Auteur]
Robe-Rybkine, Tania [Auteur]
Le-Hoang, Marie [Auteur]
Brinkman, Nathan [Auteur]
Gentinetta, Thomas [Auteur]
Edler, Monika [Auteur]
Petrillo, Sara [Auteur]
Tolosano, Emanuela [Auteur]
Miescher, Sylvia [Auteur]
Le Jeune, Sylvain [Auteur]
Houillier, Pascal [Auteur]
Chauvet, Sophie [Auteur]
Rabant, Marion [Auteur]
Dimitrov Jordan, D [Auteur]
Fremeaux-Bacchi, Veronique [Auteur]
Blanc-Brude Olivier, P [Auteur]
Roumenina Lubka, T [Auteur]
Unité de Catalyse et Chimie du Solide - UMR 8181 [UCCS]
Grunenwald, Anne [Auteur]
Rajaratnam, Helena [Auteur]
Gnemmi, Viviane [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Frimat, Marie [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lille Inflammation Research International Center (LIRIC) - U995
Figueres, Marie-Lucile [Auteur]
Knockaert, Samantha [Auteur]
Bouzekri, Sanah [Auteur]
Charue, Dominique [Auteur]
Noe, Remi [Auteur]
Robe-Rybkine, Tania [Auteur]
Le-Hoang, Marie [Auteur]
Brinkman, Nathan [Auteur]
Gentinetta, Thomas [Auteur]
Edler, Monika [Auteur]
Petrillo, Sara [Auteur]
Tolosano, Emanuela [Auteur]
Miescher, Sylvia [Auteur]
Le Jeune, Sylvain [Auteur]
Houillier, Pascal [Auteur]
Chauvet, Sophie [Auteur]
Rabant, Marion [Auteur]
Dimitrov Jordan, D [Auteur]
Fremeaux-Bacchi, Veronique [Auteur]
Blanc-Brude Olivier, P [Auteur]
Roumenina Lubka, T [Auteur]
Titre de la revue :
JCI insight
Nom court de la revue :
JCI Insight
Numéro :
3
Date de publication :
2018-06-21
ISSN :
2379-3708
2379-3708
2379-3708
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
In hemolytic diseases, such as sickle cell disease (SCD), intravascular hemolysis results in the release of hemoglobin, heme, and heme-loaded membrane microvesicles in the bloodstream. Intravascular hemolysis is thus ...
Lire la suite >In hemolytic diseases, such as sickle cell disease (SCD), intravascular hemolysis results in the release of hemoglobin, heme, and heme-loaded membrane microvesicles in the bloodstream. Intravascular hemolysis is thus associated with inflammation and organ injury. Complement system can be activated by heme in vitro. We investigated the mechanisms by which hemolysis and red blood cell (RBC) degradation products trigger complement activation in vivo. In kidney biopsies of SCD nephropathy patients and a mouse model with SCD, we detected tissue deposits of complement C3 and C5b-9. Moreover, drug-induced intravascular hemolysis or injection of heme or hemoglobin in mice triggered C3 deposition, primarily in kidneys. Renal injury markers (Kim-1, NGAL) were attenuated in C3-/- hemolytic mice. RBC degradation products, such as heme-loaded microvesicles and heme, induced alternative and terminal complement pathway activation in sera and on endothelial surfaces, in contrast to hemoglobin. Heme triggered rapid P selectin, C3aR, and C5aR expression and downregulated CD46 on endothelial cells. Importantly, complement deposition was attenuated in vivo and in vitro by heme scavenger hemopexin. In conclusion, we demonstrate that intravascular hemolysis triggers complement activation in vivo, encouraging further studies on its role in SCD nephropathy. Conversely, heme inhibition using hemopexin may provide a novel therapeutic opportunity to limit complement activation in hemolytic diseases.Lire moins >
Lire la suite >In hemolytic diseases, such as sickle cell disease (SCD), intravascular hemolysis results in the release of hemoglobin, heme, and heme-loaded membrane microvesicles in the bloodstream. Intravascular hemolysis is thus associated with inflammation and organ injury. Complement system can be activated by heme in vitro. We investigated the mechanisms by which hemolysis and red blood cell (RBC) degradation products trigger complement activation in vivo. In kidney biopsies of SCD nephropathy patients and a mouse model with SCD, we detected tissue deposits of complement C3 and C5b-9. Moreover, drug-induced intravascular hemolysis or injection of heme or hemoglobin in mice triggered C3 deposition, primarily in kidneys. Renal injury markers (Kim-1, NGAL) were attenuated in C3-/- hemolytic mice. RBC degradation products, such as heme-loaded microvesicles and heme, induced alternative and terminal complement pathway activation in sera and on endothelial surfaces, in contrast to hemoglobin. Heme triggered rapid P selectin, C3aR, and C5aR expression and downregulated CD46 on endothelial cells. Importantly, complement deposition was attenuated in vivo and in vitro by heme scavenger hemopexin. In conclusion, we demonstrate that intravascular hemolysis triggers complement activation in vivo, encouraging further studies on its role in SCD nephropathy. Conversely, heme inhibition using hemopexin may provide a novel therapeutic opportunity to limit complement activation in hemolytic diseases.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Inserm
Université de Lille
CHU Lille
Université de Lille
CHU Lille
Collections :
Équipe(s) de recherche :
Glycation from inflammation to aging
Date de dépôt :
2019-03-01T14:08:06Z